, the event-driven marketing technology firm, told investors that following the deal with Allay to be an exclusive supplier of customer acquisition and lead generation, it has yielded “significant benefits”.
Mporium managed to bill over £1 million in revenues for each of the past two weeks, this compares to £1.2 million in revenues it billed for the entire first half of 2018.
Nelius De Groot, CEO of Mporium said: "We are delighted that the Agreement has achieved such strong support from our Shareholders. This is a transformational deal for Mporium, and the benefits of this partnership are already visible in the increased revenues that we are billing.”
Shares in Mporium were up 13% following the announcement
He added: “The growth of consumer regulation is a global phenomenon and this Agreement provides Mporium with a critical footprint in lead generation within the consumer regulation sector."
Mporium said that its customer acquisition and lead generation is already starting off strong, as it reaches out via digital platforms for breaches of consumer regulation.
It expects strong growth in demand for lead generation in consumer regulation market as the increasing standardisation and prescriptive compensation continues across many industries from packaged bank accounts to flight compensation.
Follow News & Updates from Mporium here:
Peter Webb, fund manager turned market commentator looks at PCF Group.
SP Angel morning look at commodities and miners, featuring: Anglo Asian Mining (AAZ LN) BUY – 96p (from 108p) – Earnings update Glencore (GLEN LN) – Glencore claim record EBITDA on strong copper mine performance Landore Resources (LND LN) – BAM Gold Preliminary Economic Assessment Pan African Resources (PAF LN) – Earnings climb as operations refocus on profitable ounces Transense Technologies plc (TRT LN) – 2nd mining contract announced this week for mining heavy truck tracking & tyre pressure monitoring
In a conference call to investors and analysts, Motif Bio confirmed that the FDA had no questions over the clinical efficacy of Iclaprim. However the FDA stated it needs additional data to further evaluate the risk for liver toxicity before the NDA approval.
Five financial stories, trending today in a 70 second podcast, including: The number of people in work in the UK has continued to climb, with a record 32.6 million employed between October and December The jobless rate, remaining at 4%, is at its lowest since early 1975.